| __timestamp | Exelixis, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2043000 | 12665000 |
| Thursday, January 1, 2015 | 3895000 | 20202000 |
| Friday, January 1, 2016 | 6552000 | 32407000 |
| Sunday, January 1, 2017 | 15066000 | 35219000 |
| Monday, January 1, 2018 | 26348000 | 36386000 |
| Tuesday, January 1, 2019 | 33097000 | 43081000 |
| Wednesday, January 1, 2020 | 36272000 | 39330000 |
| Friday, January 1, 2021 | 52873000 | 43283000 |
| Saturday, January 1, 2022 | 57909000 | 48316000 |
| Sunday, January 1, 2023 | 72547000 | 54634000 |
| Monday, January 1, 2024 | 0 |
Unleashing insights
In the competitive landscape of biotechnology and medical devices, Exelixis, Inc. and MiMedx Group, Inc. have shown distinct trajectories in their cost of revenue from 2014 to 2023. Exelixis, Inc. has experienced a remarkable growth, with its cost of revenue surging by over 3,400% from 2014 to 2023. This reflects the company's expanding operations and increased production costs as it scales its innovative cancer therapies. In contrast, MiMedx Group, Inc. has seen a more modest increase of approximately 330% over the same period, indicating a steady but less aggressive expansion in its regenerative medicine offerings. By 2023, Exelixis, Inc.'s cost of revenue reached a peak, surpassing MiMedx Group, Inc. by about 33%. This comparison highlights the dynamic nature of the industry and the strategic decisions companies make to balance growth and cost efficiency.
Cost of Revenue Trends: Gilead Sciences, Inc. vs MiMedx Group, Inc.
Analyzing Cost of Revenue: Regeneron Pharmaceuticals, Inc. and MiMedx Group, Inc.
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and MiMedx Group, Inc.'s Expenses
Cost of Revenue Comparison: BeiGene, Ltd. vs MiMedx Group, Inc.
Catalent, Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Sarepta Therapeutics, Inc. vs Exelixis, Inc.
Cost of Revenue: Key Insights for Exelixis, Inc. and PTC Therapeutics, Inc.
Cost of Revenue Comparison: Exelixis, Inc. vs Viridian Therapeutics, Inc.
Gross Profit Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.
Lantheus Holdings, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Galapagos NV vs MiMedx Group, Inc.
Cost of Revenue Comparison: Viridian Therapeutics, Inc. vs MiMedx Group, Inc.